Q2 2020 EPS Estimates for STAAR Surgical (NASDAQ:STAA) Lowered by William Blair

STAAR Surgical (NASDAQ:STAA) – Research analysts at William Blair reduced their Q2 2020 EPS estimates for shares of STAAR Surgical in a report issued on Thursday, August 1st. William Blair analyst B. Weinstein now forecasts that the medical instruments supplier will post earnings of $0.14 per share for the quarter, down from their previous estimate of $0.15. William Blair also issued estimates for STAAR Surgical’s FY2020 earnings at $0.54 EPS.

Several other research firms have also commented on STAA. Zacks Investment Research lowered shares of STAAR Surgical from a “buy” rating to a “hold” rating in a research report on Friday, August 2nd. Canaccord Genuity reiterated a “buy” rating and set a $38.00 price objective (down previously from $43.00) on shares of STAAR Surgical in a research report on Monday, May 6th. ValuEngine upgraded shares of STAAR Surgical from a “hold” rating to a “buy” rating in a research report on Wednesday, May 1st. Finally, BidaskClub lowered shares of STAAR Surgical from a “buy” rating to a “hold” rating in a research report on Wednesday. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $42.00.

Shares of NASDAQ:STAA opened at $32.75 on Monday. The company has a current ratio of 5.53, a quick ratio of 4.97 and a debt-to-equity ratio of 0.04. The stock’s fifty day moving average is $30.56. STAAR Surgical has a fifty-two week low of $21.70 and a fifty-two week high of $54.00. The company has a market capitalization of $1.49 billion, a price-to-earnings ratio of 116.96 and a beta of 2.24.

STAAR Surgical (NASDAQ:STAA) last issued its earnings results on Wednesday, July 31st. The medical instruments supplier reported $0.14 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.10 by $0.04. STAAR Surgical had a net margin of 5.80% and a return on equity of 12.81%. The firm had revenue of $39.66 million during the quarter, compared to analyst estimates of $40.10 million.

A number of hedge funds have recently added to or reduced their stakes in the business. GSA Capital Partners LLP lifted its position in STAAR Surgical by 3.0% during the second quarter. GSA Capital Partners LLP now owns 16,720 shares of the medical instruments supplier’s stock valued at $491,000 after purchasing an additional 481 shares during the last quarter. AdvisorNet Financial Inc lifted its position in STAAR Surgical by 54.8% during the second quarter. AdvisorNet Financial Inc now owns 1,742 shares of the medical instruments supplier’s stock valued at $51,000 after purchasing an additional 617 shares during the last quarter. Legal & General Group Plc lifted its position in STAAR Surgical by 12.7% during the fourth quarter. Legal & General Group Plc now owns 7,616 shares of the medical instruments supplier’s stock valued at $243,000 after purchasing an additional 857 shares during the last quarter. American Century Companies Inc. lifted its position in STAAR Surgical by 0.5% during the fourth quarter. American Century Companies Inc. now owns 175,398 shares of the medical instruments supplier’s stock valued at $5,597,000 after purchasing an additional 892 shares during the last quarter. Finally, Advisor Group Inc. lifted its position in STAAR Surgical by 4.3% during the second quarter. Advisor Group Inc. now owns 22,817 shares of the medical instruments supplier’s stock valued at $670,000 after purchasing an additional 937 shares during the last quarter. Institutional investors and hedge funds own 89.72% of the company’s stock.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.

See Also: Dividend Achievers

Earnings History and Estimates for STAAR Surgical (NASDAQ:STAA)

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.